Evidence map›Paper›PMID 32170867›Full record

Trial reportAmerican journal of hematology2020

Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia.

Koji Sasaki, Hagop Kantarjian, William Wierda, Farhad Ravandi-Kashani, Jeffrey Jorgensen, Sa A Wang, Joseph Khoury, Naval Daver, Jan Burger, Courtney D Di Nardo and 15 more

Open access · bronzeAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Therapeutic Advances in Immunotherapies for Hematological Malignancies.International journal of molecular sciences · 2022
    Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 3 institutions in 2 countries.

Koji SasakiDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Hagop KantarjianDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
William WierdaDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Farhad Ravandi-KashaniDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Jeffrey JorgensenDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Sa A WangDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Joseph KhouryDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Naval DaverDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-7103-373X
Jan BurgerDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Courtney D Di NardoDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-9003-0390
Nitin JainDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Nicholas J ShortDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-2983-2738
Zeev Estrov MdDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Marina Konopleva Md PhDDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-9347-2212
Maro Ohanian DODepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-1689-4470
Guillermo Garcia-ManeroDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Tapan KadiaDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-9892-9832
Yesid Alvarado-ValeroDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Musa YilmazDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-4498-4895
Sherry PierceDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Rebecca GarrisDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
April IngramDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0003-4959-8819
Jorge CortesGeorgia Cancer Center, Augusta, Georgia, USA.
Susan OʼBrienChao Family Comprehensive Cancer Center, University of California Irvine, Orange, California, USA.
Elias JabbourDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0003-4465-6119
The University of Texas MD Anderson Cancer Center · USNational Cancer Center of Georgia · GEUniversity of California, Irvine · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Liposomal vincristine is designed to reduce neurotoxicity and increase dose intensity delivery, and has been approved as salvage therapy in relapsed/refractory acute lymphoblastic leukemia (ALL). Our aim was to evaluate the response rate, toxicities, and outcome of adults with newly diagnosed ALL who received liposomal vincristine, rather than regular vincristine in combination with intensive chemotherapy (Hyper-CMAD). In a single-center, phase 2 study, patients ≥18 years with newly-diagnosed B-cell ALL were eligible to receive hyper-CMAD alternating with high-dose methotrexate and cytarabine. Rituximab was administered in CD20 positive ALL. Tyrosine kinase inhibitors (imatinib or dasatinib) were added in Philadelphia chromosome-positive (Ph-positive) ALL. Thirty-one patients were enrolled, median follow-up of 59 months (0.3-70). Thirteen patients (42%) had CD20 positive ALL, and 21 (68%) had Ph-positive ALL. Thirty (97%) achieved complete remission (CR). All 26 patients with abnormal karyotype achieved complete cytogenetic response (CCyR), and 27/30 (90%) achieved negative minimal residual disease status by multicolor flow cytometry. Of 20 evaluable Ph-positive ALL patients, major molecular response (MMR) was achieved in 19 patients (95%); complete molecular response (CMR) in 14 (70%). Grade 3/4 peripheral neuropathy was observed in five (16%) with all grade peripheral neuropathy in 21 (68%). With a median follow-up of 59 months, 21 (68%) patients are alive. The 5-year CR duration and survival rates were 73% and 61%, respectively. Ten (32%) patients died: one, sepsis on C1D10; four, unknown; one, post-transplant complications; four, relapse. Hyper-CMAD with liposomal vincristine is safe and demonstrated high response and survival rates in newly diagnosed ALL.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCytarabineDisease-Free SurvivalFemaleFollow-Up StudiesHumansLiposomesMaleMethotrexateMiddle AgedPrecursor B-Cell Lymphoblastic Leukemia-LymphomaRituximabSurvival RateCytarabineLiposomesMethotrexateRituximabVincristine

Identifiers

PMID32170867
PMCPMC11809050
OpenAlexW3011401084

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.